Generation of the Complement Activation Product C5a Precedes Interleukin-2-Induced Capillary Leakage Syndrome

Journal of Immunotherapy

Volumn 19, Issue 1, 1996, Pages 45-49

  Nurnberger W ^a   Holthausen, S ^a   Michelmann, I ^a   Jurgens H ^b   Burdach, S ^a   Gobel U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

C5a; Capillary leakage syndrome; Complement activation; IL 2

Indexed keywords

COMPLEMENT COMPONENT C5A; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; LUNG EDEMA; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; SHOCK; SOLID TUMOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CAPILLARY LEAK SYNDROME; CHILD; COMPLEMENT C5A; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; RECOMBINANT PROTEINS;

EID: 0029931854     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199601000-00005     Document Type: Article

References (17)

1. Dilloo D, Laws HJ, Hanenberg H, Körholz D, Nürnberger W, Burdach SEG. Induction of two distinct NK-cell populations, activated T-cells and antineoplastic cytokines by IL-2 therapy in children with solid tumors. Exp Hematol 1994;22:1081-8.
2. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;137: 1735-42.
3. Lissoni P, Barni S, Cattaneo G, et al. Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leakage syndrome. Int J Biol Markers 1990;5:195-7.
4. Thijs LG, Hack CE, Strack van Schijndel RJM, et al. Activation of complement system during immunotherapy with recombinant 1L-2. J Immunol 1990;144:2419-24.
5. Hugli TE. Structure and functions of the anaphylatoxins. Springer Semin Immunopathol 1984;7:193-219.
6. Jose PJ, Forest MJ, Williams TJ. Human C5a desArg increases vascular permeability. J Exp Med 1983;158:2177-82.
7. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N, Henson PM. Adherence of neutrophils to cultured human microvascular endothelial cells. J Clin Invest 1989; 83(2):637-46.
8. Klos A, Ihrig V, Messmer M, Grabbe J, Bitter-Suermann D. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies. J Immunol Methods 1988;111:241-52.
9. Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Meir JW. Complement activation in cancer patients undergoing immunotherapy with interleukin-2: binding of complement and C-reactive protein to IL-2 activated lymphocytes. Blood 1991;78:2505-13.
10. Okusawa S, Yancey KB, van der Meer JWM, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. J Exp Med 1988;168:443-8.
11. Ghebrehiwet B, Randazzo BR, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983;71:1450-6.
12. Mammen EF. Contact activation: the interaction of clotting, fibrinolytic, kinin and complement systems. Biomed Prog 1990;2:31-3.
13. Hack CE, Wagstaff J, Strack van Schijndel RJM, et al. Studies of the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock. Thromb Haemost 1991;65(5):497-503.
14. Varga L, Poros A, Puskás E, et al. Clinical significance of longitudinal complement measurements in recipients of bone marrow transplant. Bone Marrow Transplant 1995;15:509-14.
15. Deehan DJ, Heys SD, Simpson W, Herriot R, Broom J, Eremin O. Correlation of serum cytokine and acute phase reactant levels with alterations in weight and albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol 1994;95:366-72.
16. Nürnberger W, Petrik K, Burdach S, Göbel U. C1 esterase inhibitor can reduce plasma concentrations of the complement activation product C5a [Letter]. Intensive Care Med 1994;20:242.
17. Hack CE, Ogilie AC, Eisele B, Eerenberg AJM, Wagstaff J, Thijs LG. C1 inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993;19(suppl):19-28.